Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 2:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Immune Modulation Clear all
Suspended Phase 1 Interventional

Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant

NCT02333162
View directory record Official record
Conditions
Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Hematologic Malignancy
Interventions
Fludarabine Phosphate, Melphalan, Intensity-Modulated Radiation Therapy, Total Marrow Irradiation, Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Allogeneic Bone Marrow Transplantation, Tacrolimus, Mycophenolate Mofetil, Laboratory Biomarker Analysis
Drug · Radiation · Procedure + 1 more
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jul 21, 2026, 2:12 PM EDT
Recruiting Phase 2 Interventional

Modulation of the Immune System in Down Syndrome for Improved Outcomes and Neurodevelopment - 1

NCT07598643
View directory record Official record
Conditions
Down Syndrome
Interventions
Tofacitinib Oral Solution, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Years to 22 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 21, 2026, 2:12 PM EDT
Completed Not applicable Interventional

UNITE Study (UMN-GE) for COVID-19

NCT04701489
View directory record Official record
Conditions
Covid19, Cytokine Storm, Inflammation
Interventions
Splenic ultrasound
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Jul 21, 2026, 2:12 PM EDT
Terminated Phase 1 Interventional

Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma

NCT01216436
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Vaccination with RNA-transfected mature autologous DC
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 24, 2015 · Synced Jul 21, 2026, 2:12 PM EDT
Recruiting Not applicable Interventional

Ultrasound Neuroimmune Modulation in Adults With Rheumatoid Arthritis

NCT07293871
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Active treatment, Sham (No Treatment)
Device
Lead sponsor
Surf Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Colleyville, Texas • Dallas, Texas • Irving, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 21, 2026, 2:12 PM EDT
Completed Phase 2 Interventional

dnaJ Peptide for Relieving Rheumatoid Arthritis

NCT00000435
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
dnaJ peptide, None-placebo
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 85 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
8
States / cities
Tucson, Arizona • Orange, California • Palo Alto, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2007 · Synced Jul 21, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of mTOR Inhibition and Other Metabolism Modulating Interventions on the Elderly

NCT02874924
View directory record Official record
Conditions
Aging
Interventions
Rapamycin, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
70 Years to 95 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced Jul 21, 2026, 2:12 PM EDT
Not yet recruiting No phase listed Observational

Retrospective Kinetic Safety Evaluation of an Intravenous Micellar Excipient Platform

NCT07609069
View directory record Official record
Conditions
Drug Related Side Effects and Adverse Reactions, Infusion Reactions
Interventions
PIV-850 (850-picometer Dual-NCE Acidic Matrix), Legacy Heterogeneous Payload (Micellar Vehicle)
Drug
Lead sponsor
PICO IV, Inc.
Industry
Eligibility
18 Years and older
Enrollment
625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 21, 2026, 2:12 PM EDT
Terminated Phase 2 Interventional Results available

Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes

NCT00837759
View directory record Official record
Conditions
Diabetes Mellitus Type 1, Autoimmune Diabetes
Interventions
Insulin, Lansoprazole, Sitagliptin, Diamyd, GAD65 (Diamyd)
Drug · Biological
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
16 Years to 30 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced Jul 21, 2026, 2:12 PM EDT
Completed Phase 1 Interventional

Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit

NCT01527838
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease, Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Interventions
Single FT1050 treated UCB unit
Biological
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Boston, Massachusetts • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 11, 2016 · Synced Jul 21, 2026, 2:12 PM EDT
Completed Phase 2 Interventional

Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma

NCT00002535
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
aldesleukin, lymphokine-activated killer cells, therapeutic tumor infiltrating lymphocytes, cyclophosphamide, indomethacin
Biological · Drug
Lead sponsor
St. Luke's Medical Center
Other
Eligibility
17 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2004
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Jul 21, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

Modulation of Immune Activation by Aspirin

NCT02155985
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Aspirin, Placebo
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Jul 21, 2026, 2:12 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Systemically Administered Hydrocortisone on the Immune System in Healthy Volunteers

NCT01281995
View directory record Official record
Conditions
Immunosuppression, Healthy, Healthy Subjects
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2018 · Synced Jul 21, 2026, 2:12 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Effect of Rosiglitazone on Peritoneal Cytokines in Women With Endometriosis

NCT00121953
View directory record Official record
Conditions
Endometriosis
Interventions
Rosiglitazone
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 16, 2012 · Synced Jul 21, 2026, 2:12 PM EDT
Completed Not applicable Interventional

Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies

NCT00068523
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, UV light therapy, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 26, 2020 · Synced Jul 21, 2026, 2:12 PM EDT
Recruiting Phase 2 Interventional

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

NCT05915442
View directory record Official record
Conditions
Oligometastatic Prostate Cancer
Interventions
Quemliclustat, Etrumadenant, Zimberelimab, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
Catherine Spina
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2025 · Synced Jul 21, 2026, 2:12 PM EDT
Completed Phase 2 Interventional

Monocyte Function and Inflammation in Type 1 Diabetes and Its Modulation

NCT00441844
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Simvastatin
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
20 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2007 · Synced Jul 21, 2026, 2:12 PM EDT
Completed Phase 1 Interventional

Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma

NCT00002759
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Neutropenia, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cyclosporine, irinotecan hydrochloride, phenobarbital
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Jul 21, 2026, 2:12 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

AMPLIFI: Adaptive Modulation of Plasticity Through Lactate and Fitness Interventions

NCT06950060
View directory record Official record
Conditions
Stroke, Chronic, Aging, Cognitive Decline, Motor Dysfunction, Neuroplasticity
Interventions
High intensity cycling, Low-intensity cycling, Health education session, Moderate Intensity Aerobic Exercise
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 21, 2026, 2:12 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors

NCT02174172
View directory record Official record
Conditions
Solid Cancers
Interventions
Atezolizumab, Bevacizumab, Interferon alfa-2b, Ipilimumab, Obinutuzumab, PEG-interferon alfa-2a
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
8
States / cities
Scottsdale, Arizona • Los Angeles, California • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Jul 21, 2026, 2:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Immunologic Effects of Echinacea

NCT00860795
View directory record Official record
Conditions
Upper Respiratory Tract Infections
Interventions
Echinacea purpurea, placebo
Biological · Drug
Lead sponsor
University of Washington
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Kenmore, Washington
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Jul 21, 2026, 2:12 PM EDT
Withdrawn Phase 1Phase 2 Interventional

A Study of Neoadjuvant Photodynamic Immunomodulation for Colon Cancer

NCT01522677
View directory record Official record
Conditions
Colon Cancer
Interventions
PDT with 5-ALA radiosensitization
Drug
Lead sponsor
Edward Nelson
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Orange, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Jul 21, 2026, 2:12 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults

NCT01103284
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
DiaPep277, Placebo
Drug
Lead sponsor
Andromeda Biotech Ltd.
Industry
Eligibility
20 Years to 45 Years
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
26
States / cities
Los Gatos, California • Modesto, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Jul 21, 2026, 2:12 PM EDT
Terminated Not applicable Interventional

Preoperative Nutrition With Immune Enhancing Nutritional Supplement (Immunomodulation)

NCT02838966
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Nestle IMPACT Advanced Recovery, Nestle Boost High Protein Drink
Dietary Supplement
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Jul 21, 2026, 2:12 PM EDT